Clinical case: idelalisib-induced immunoglobulin flare

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• IgM flare is a known complication in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) patients treated with specific therapies like Cladribine and Rituximab.
• This phenomenon involves a transient increase in monoclonal IgM levels.
• Previous literature has primarily documented IgM flares in the context of LPL/WM.

Observation:

• A case report details a heavily pretreated chronic lymphocytic leukemia (CLL) patient with unusually high immunoglobulin production.
• This patient developed a clinically significant immunoglobulin flare after initiating Idelalisib treatment.
• This observation extends the understanding of IgM flare beyond LPL/WM.

Findings:

• The study identifies Idelalisib as a potential trigger for IgM flare in CLL patients.
• This represents a novel occurrence of clinically significant immunoglobulin flare in CLL.
• The patient exhibited atypically high immunoglobulin production, potentially predisposing them to this event.

Implications:

• This case broadens the spectrum of conditions and treatments associated with IgM flare.
• It suggests the need for vigilance regarding immunoglobulin flares in CLL patients receiving Idelalisib.
• Further research may elucidate the mechanisms underlying Idelalisib-induced IgM flares and identify at-risk patient populations.